Chien‐Wei Su

8.4k total citations
229 papers, 6.0k citations indexed

About

Chien‐Wei Su is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Chien‐Wei Su has authored 229 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 189 papers in Hepatology, 169 papers in Epidemiology and 44 papers in Surgery. Recurrent topics in Chien‐Wei Su's work include Liver Disease Diagnosis and Treatment (146 papers), Hepatocellular Carcinoma Treatment and Prognosis (115 papers) and Hepatitis B Virus Studies (70 papers). Chien‐Wei Su is often cited by papers focused on Liver Disease Diagnosis and Treatment (146 papers), Hepatocellular Carcinoma Treatment and Prognosis (115 papers) and Hepatitis B Virus Studies (70 papers). Chien‐Wei Su collaborates with scholars based in Taiwan, United States and United Kingdom. Chien‐Wei Su's co-authors include Yi‐Hsiang Huang, Teh‐Ia Huo, Han‐Chieh Lin, Jaw‐Ching Wu, Jaw‐Ching Wu, Cheng‐Yuan Hsia, Shou‐Dong Lee, Chia‐Yang Hsu, Yi‐You Chiou and Fa‐Yauh Lee and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Chien‐Wei Su

216 papers receiving 5.9k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Chien‐Wei Su 4.5k 3.8k 1.2k 909 874 229 6.0k
Maria Guido 4.1k 0.9× 4.0k 1.1× 1.4k 1.2× 719 0.8× 515 0.6× 178 6.4k
Si Hyun Bae 3.9k 0.9× 2.7k 0.7× 1.1k 0.9× 818 0.9× 672 0.8× 250 5.6k
Hiroshi Aikata 3.3k 0.7× 2.3k 0.6× 1.1k 0.9× 608 0.7× 567 0.6× 254 4.8k
Chae Yoon Chon 5.1k 1.1× 4.4k 1.2× 1.3k 1.1× 615 0.7× 472 0.5× 196 6.6k
Byung Chul Yoo 3.7k 0.8× 2.9k 0.8× 1.3k 1.1× 537 0.6× 363 0.4× 135 4.8k
Lünan Yan 3.2k 0.7× 2.3k 0.6× 2.2k 1.9× 781 0.9× 464 0.5× 275 5.1k
Won Young Tak 3.4k 0.7× 2.3k 0.6× 1.4k 1.2× 901 1.0× 863 1.0× 201 5.9k
Jeong Won Jang 3.1k 0.7× 2.3k 0.6× 656 0.6× 851 0.9× 625 0.7× 219 4.4k
Jean–Claude Trinchet 5.1k 1.1× 5.2k 1.4× 1.2k 1.0× 505 0.6× 347 0.4× 117 7.0k
Kelvin K. Ng 3.0k 0.7× 1.7k 0.4× 1.9k 1.6× 1.3k 1.4× 554 0.6× 136 4.9k

Countries citing papers authored by Chien‐Wei Su

Since Specialization
Citations

This map shows the geographic impact of Chien‐Wei Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chien‐Wei Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chien‐Wei Su more than expected).

Fields of papers citing papers by Chien‐Wei Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chien‐Wei Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chien‐Wei Su. The network helps show where Chien‐Wei Su may publish in the future.

Co-authorship network of co-authors of Chien‐Wei Su

This figure shows the co-authorship network connecting the top 25 collaborators of Chien‐Wei Su. A scholar is included among the top collaborators of Chien‐Wei Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chien‐Wei Su. Chien‐Wei Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Chih-Jen, Shiao‐Ya Hong, Hwai‐I Yang, et al.. (2025). Triglyceride-glucose index and cancer risk: a prospective cohort study in Taiwan. Diabetology & Metabolic Syndrome. 17(1). 283–283. 1 indexed citations
2.
Tan, Elise Chia‐Hui, Wei‐Yu Kao, Pei‐Chang Lee, et al.. (2024). The association between proton‐pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy. Journal of Gastroenterology and Hepatology. 39(10). 2077–2087. 1 indexed citations
3.
Ho, Shu‐Yein, Po‐Hong Liu, Yi‐Hsiang Huang, et al.. (2023). Albumin-Based Liver Reserve Models vs. MELD 3.0 in Prognostic Prediction for Hepatocellular Carcinoma Patients with Renal Insufficiency. International Journal of Molecular Sciences. 24(23). 16987–16987. 6 indexed citations
4.
Ho, Shu‐Yein, Po‐Hong Liu, Yi‐Hsiang Huang, et al.. (2023). Comparison of Four Albumin-Based Liver Reserve Models (ALBI/EZ-ALBI/PALBI/PAL) against MELD for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Cancers. 15(7). 1925–1925. 13 indexed citations
5.
Ho, Shu‐Yein, Po‐Hong Liu, Cheng‐Yuan Hsia, et al.. (2022). Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin–bilirubin grade. International Journal of Clinical Oncology. 27(4). 739–748. 6 indexed citations
6.
Wang, Tsae‐Jyy, et al.. (2022). Efficacy of a Decision Support Intervention on Decisional Conflict Related to Hepatocellular Cancer Treatment: A Randomized Controlled Trial. Clinical Nursing Research. 32(1). 233–243. 1 indexed citations
7.
Lee, I‐Cheng, Keng‐Hsin Lan, Chien‐Wei Su, et al.. (2022). Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. International Journal of Molecular Sciences. 23(19). 11335–11335. 4 indexed citations
8.
Ho, Shu‐Yein, Po‐Hong Liu, Yi‐Hsiang Huang, et al.. (2022). Radiofrequency Ablation versus Transarterial Chemoembolization for Hepatocellular Carcinoma within Milan Criteria: Prognostic Role of Tumor Burden Score. Cancers. 14(17). 4207–4207. 6 indexed citations
9.
Ho, Shu‐Yein, Po‐Hong Liu, Yi‐Hsiang Huang, et al.. (2022). A New Tumor Burden Score and Albumin–Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. Cancers. 14(3). 649–649. 18 indexed citations
10.
Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2021). Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatology Research. 51(11). 1129–1138. 16 indexed citations
11.
Lee, I‐Cheng, Rheun‐Chuan Lee, Ya‐Wen Hung, et al.. (2021). Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. Cancers. 13(17). 4325–4325. 9 indexed citations
12.
Ho, Shu‐Yein, Chia‐Yang Hsu, Po‐Hong Liu, et al.. (2020). Albumin–Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Digestive Diseases and Sciences. 66(5). 1730–1738. 13 indexed citations
13.
Liu, Po‐Hong, Chia‐Yang Hsu, Chien‐Wei Su, et al.. (2020). Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver International. 40(10). 2522–2534. 31 indexed citations
14.
Chiou, Yi‐You, Nai‐Chi Chiu, Chien-An Liu, et al.. (2020). Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation. Scientific Reports. 10(1). 2006–2006. 10 indexed citations
15.
Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2019). A New Prognostic Model Based on Albumin–Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. Digestive Diseases and Sciences. 65(2). 658–667. 11 indexed citations
16.
Lee, I‐Cheng, Ya‐Wen Hung, Chien‐An Liu, et al.. (2019). A new ALBI‐based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver International. 39(9). 1704–1712. 76 indexed citations
17.
Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2018). Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Scientific Reports. 8(1). 4773–4773. 32 indexed citations
18.
Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2018). Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Scientific Reports. 8(1). 15074–15074. 14 indexed citations
19.
Ho, Shu‐Yein, Po‐Hong Liu, Chia‐Yang Hsu, et al.. (2018). Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Scientific Reports. 8(1). 843–843. 27 indexed citations
20.
Kao, Wei‐Yu, Chien‐Wei Su, Elise Chia‐Hui Tan, et al.. (2018). Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology. 69(3). 1151–1164. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Guido Breakdown of academic impact, for papers by Si Hyun Bae Breakdown of academic impact, for papers by Hiroshi Aikata Breakdown of academic impact, for papers by Chae Yoon Chon Breakdown of academic impact, for papers by Byung Chul Yoo Breakdown of academic impact, for papers by Lünan Yan Breakdown of academic impact, for papers by Won Young Tak Breakdown of academic impact, for papers by Jeong Won Jang Breakdown of academic impact, for papers by Jean–Claude Trinchet Breakdown of academic impact, for papers by Kelvin K. Ng
Rankless by CCL
2026